Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors.
CA9
clear cell renal cell carcinoma
dual antigen T cell engagers
glioblastoma
hypoxic niche
immunotherapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
03
2022
accepted:
31
05
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
Glioblastomas (GBM), the most common malignant primary adult brain tumors, are uniformly lethal and are in need of improved therapeutic modalities. GBM contain extensive regions of hypoxia and are enriched in therapy resistant brain tumor-initiating cells (BTICs). Carbonic anhydrase 9 (CA9) is a hypoxia-induced cell surface enzyme that plays an important role in maintenance of stem cell survival and therapeutic resistance. Here we demonstrate that CA9 is highly expressed in patient-derived BTICs. CA9
Identifiants
pubmed: 35874663
doi: 10.3389/fimmu.2022.905768
pmc: PMC9296860
doi:
Substances chimiques
Antigens, Neoplasm
0
CA9 protein, human
EC 4.2.1.1
Carbonic Anhydrase IX
EC 4.2.1.1
Carbonic Anhydrases
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
905768Informations de copyright
Copyright © 2022 Tatari, Zhang, Chafe, McKenna, Lawson, Subapanditha, Shaikh, Seyfrid, Savage, Venugopal, Moffat and Singh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Cell. 2009 Jun 2;15(6):501-13
pubmed: 19477429
Clin Cancer Res. 2003 Feb;9(2):802-11
pubmed: 12576453
Cancer Res. 2015 Jun 1;75(11):2166-76
pubmed: 25840983
Neuro Oncol. 2016 Feb;18(2):160-72
pubmed: 26180081
Gastroenterology. 2019 Sep;157(3):823-837
pubmed: 31078621
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Br J Cancer. 2004 Mar 8;90(5):985-90
pubmed: 14997194
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
ESMO Open. 2017 Feb 22;1(6):e000144
pubmed: 28912963
Oncotarget. 2012 Jan;3(1):84-97
pubmed: 22289741
Mol Cell Neurosci. 2007 Jul;35(3):424-35
pubmed: 17498968
BMC Cancer. 2016 Jul 16;16:485
pubmed: 27422173
Am J Pathol. 2012 May;180(5):2108-19
pubmed: 22440258
Methods Mol Biol. 2014;1210:37-49
pubmed: 25173159
Cell Stem Cell. 2020 Jun 4;26(6):832-844.e6
pubmed: 32464096
Cancer Immunol Res. 2019 Jul;7(7):1064-1078
pubmed: 31088846
Eur Urol. 2016 May;69(5):767-70
pubmed: 26706103
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
Nat Immunol. 2019 Sep;20(9):1100-1109
pubmed: 31358997
Neuro Oncol. 2012 Nov;14(11):1357-66
pubmed: 23074198
Curr Opin Urol. 2021 May 1;31(3):249-254
pubmed: 33742975
Cancer Res. 2017 Apr 15;77(8):2052-2063
pubmed: 28143835
Cell Cycle. 2009 Oct 15;8(20):3274-84
pubmed: 19770585
Nat Biotechnol. 2019 Sep;37(9):1049-1058
pubmed: 31332324
J Med Chem. 2011 Mar 24;54(6):1896-902
pubmed: 21361354
J Vis Exp. 2012 Sep 25;(67):
pubmed: 23051935
J Immunother. 2007 Nov-Dec;30(8):798-807
pubmed: 18049331
Neurobiol Learn Mem. 1995 Jul;64(1):68-82
pubmed: 7582814
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34795007
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Annu Rev Med. 2007;58:267-84
pubmed: 17002552
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520
pubmed: 30733593
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Sci Transl Med. 2012 Mar 28;4(127):127ps10
pubmed: 22461637
Cancers (Basel). 2020 Jun 18;12(6):
pubmed: 32570870
PLoS One. 2014 Apr 07;9(4):e94324
pubmed: 24710513
Neuro Oncol. 2017 Jul 1;19(7):887-896
pubmed: 28339582
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6
pubmed: 22323597
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
JCI Insight. 2017 Dec 21;2(24):
pubmed: 29263302
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Onkologie. 2005 Jun;28(6-7):315-7
pubmed: 15933418
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
Cell. 2006 Mar 24;124(6):1111-5
pubmed: 16564000
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Int J Cancer. 2005 May 20;115(1):98-104
pubmed: 15688411
BMC Dev Biol. 2009 Mar 16;9:22
pubmed: 19291313
Am J Pathol. 2001 Mar;158(3):905-19
pubmed: 11238039
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
J Cell Mol Med. 2010 Apr;14(4):771-94
pubmed: 20015196
Front Physiol. 2014 Jan 08;4:400
pubmed: 24409151
Mol Cancer. 2006 Dec 02;5:67
pubmed: 17140455
Macromol Biosci. 2018 Jan;18(1):
pubmed: 28902983
Curr Pharm Des. 2010;16(29):3288-99
pubmed: 20819065
J Exp Pharmacol. 2020 Dec 15;12:603-617
pubmed: 33364855
J Clin Oncol. 2006 May 1;24(13):e20-2
pubmed: 16648493
Oncogene. 2013 Oct 31;32(44):5210-9
pubmed: 23208505
Sci Adv. 2021 Aug 27;7(35):
pubmed: 34452919
Cell Death Differ. 2008 Apr;15(4):678-85
pubmed: 18259193
Urol Int. 2005;74(1):68-73
pubmed: 15711113
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7385-90
pubmed: 19372381
Curr Pharm Des. 2010;16(29):3255-63
pubmed: 20819068
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cell. 2020 Jun 25;181(7):1626-1642.e20
pubmed: 32470397
Cancers (Basel). 2021 Jul 07;13(14):
pubmed: 34298615
Curr Oncol Rep. 2005 Mar;7(2):109-15
pubmed: 15717944
PLoS One. 2010 Oct 18;5(10):e13474
pubmed: 20976159
Cancer Immunol Res. 2013 Sep;1(3):163
pubmed: 24570975
Int J Oncol. 2014 Dec;45(6):2455-67
pubmed: 25230982
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):270-5
pubmed: 23248284
Nat Genet. 2019 Feb;51(2):308-318
pubmed: 30643250
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Neuro Oncol. 2016 Jan;18 Suppl 1:i1-i50
pubmed: 26705298